GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed 40 billion by 2031, up from 38 billion.

GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

GSK and the University of Oxford have joined hands to focus on the potential of cancer prevention through vaccination. The ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...

The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side effects.

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult patients with ...

Depemokimab data reveals 72% reduction in hospitalizations; projected sales hit £4 billion. GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from ...

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...

GSK will make a $1 billion upfront payment ... in oncology will help to accelerate the development of this novel medicine for patients," he added.

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

(MENAFN) British medicine producer GSK on Monday noted that it is going to purchase US biopharmaceutical firm IDRx for up to USD1.15 billion. The Boston-originated biotechnology company is ...